Qiagen N.V. (QGEN)
| Market Cap | 7.04B |
| Revenue (ttm) | 2.09B |
| Net Income (ttm) | 424.88M |
| Shares Out | 206.80M |
| EPS (ttm) | 2.04 |
| PE Ratio | 18.65 |
| Forward PE | 15.24 |
| Dividend | $2.41 (7.09%) |
| Ex-Dividend Date | Jan 8, 2026 |
| Volume | 7,717,784 |
| Open | 35.55 |
| Previous Close | 38.09 |
| Day's Range | 33.78 - 35.58 |
| 52-Week Range | 33.84 - 57.82 |
| Beta | 0.79 |
| Analysts | Buy |
| Price Target | 51.59 (+51.65%) |
| Earnings Date | May 6, 2026 |
About QGEN
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purif... [Read more]
Financial Performance
In 2025, Qiagen's revenue was $2.09 billion, an increase of 5.65% compared to the previous year's $1.98 billion. Earnings were $424.88 million, an increase of 408.28%.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for QGEN stock is "Buy." The 12-month stock price target is $51.59, which is an increase of 51.65% from the latest price.
News
Qiagen Transcript: Investor update
Q1 2026 delivered adjusted EPS in line with outlook, but sales missed targets due to lower QuantiFERON immigration testing and cautious U.S. life sciences demand. 2026 guidance was revised down for both sales and EPS, but strong growth is expected in H2 from new launches and efficiency gains.
QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook
VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary results for the first quarter of 2026, continuing to deli...
QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it will showcase its oncology workflow applications at the American Assoc...
QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel
HILDEN, Germany & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its expansion into syndromic testing for bloodstream in...
Parse Biosciences, a QIAGEN Company, Launches FFPE-compatible Barcoding Technology for Whole Transcriptome Single Cell Analysis
SEATTLE--(BUSINESS WIRE)--Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Everc...
Qiagen Announces Form 20-F Annual Report Filing for 2025 Results
VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidat...
QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced newly published clinical and health economic data suppo...
QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cl...
Qiagen Transcript: Barclays 28th Annual Global Healthcare Conference
Leadership transition is underway with a CEO announcement expected in Q2, while strategic alternatives remain open. New product launches and the Parse acquisition are set to drive growth and margin improvement, despite ongoing macroeconomic and funding challenges.
Qiagen Transcript: Leerink Global Healthcare Conference 2026
Leadership transition is on track with a new CEO expected in Q2 2024, while strategic reviews and M&A remain active. Revenue growth is driven by new product launches, stable consumables demand, and targeted R&D investments, with China showing signs of sequential improvement.
Qiagen Transcript: TD Cowen 46th Annual Health Care Conference
Leadership is finalizing a CEO search while actively reviewing strategic alternatives with advisors, aiming to maximize shareholder value. Growth in 2026 will be driven by new product launches, acquisitions, and improved funding visibility, with continued focus on profitability and innovation.
Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery
SEATTLE, Wash. & VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and ac...
Qiagen Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 results exceeded guidance, with strong growth in core pillars and improved profitability despite macro headwinds. 2026 outlook targets at least 5% CER sales growth and $2.50+ adjusted EPS, supported by new product launches and disciplined capital allocation.
QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the fourth quarter and full-year 2025. Net sales for Q4 2025 ...
QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the first public showcase of QIAsprint Connect at SLAS ...
QIAGEN Appoints Mark Stevenson to Supervisory Board
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Mark Stevenson has been appointed as an independent member of the Supervi...
Qiagen Explores Possible Sale After New Buyer Talks: Report
German life sciences tools company Qiagen N.V. (NYSE: QGEN) is reportedly reviewing strategic options, including a potential sale, as renewed takeover interest emerges.
Qiagen weighing strategic options amid fresh takeover interest, Bloomberg reports
Qiagen is weighing strategic options, including a potential sale of the diagnostics firm amid fresh takeover interest, Bloomberg News reported on Tuesday, citing people with knowledge of the matter.
QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the fourth quarter of 2025. Press release date / time: Wednes...
QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its 2026 priorities across its five growth pillars focused on advancing p...
Qiagen Transcript: 44th Annual J.P. Morgan Healthcare Conference
The session highlighted robust execution on growth and profitability targets, with double-digit expansion in key platforms and successful integration of recent acquisitions. Strategic investments in automation, AI, and new product launches are set to drive further growth, with a positive outlook for 2026 and beyond.
QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion of plans to return approximately $500 million to s...
Qiagen Transcript: Evercore ISI 8th Annual HealthCONx Conference
Strong consumables-driven growth and innovation offset macro headwinds, with new product launches and M&A fueling optimism for 2026. Diagnostic and sample tech segments are key growth drivers, while margin expansion is targeted through operational efficiencies and portfolio enhancements.
Qiagen Transcript: Citi Annual Global Healthcare Conference 2025
Strong growth in consumables and diagnostics, strategic acquisitions, and new product launches are driving above-industry performance. Margin expansion and robust capital allocation continue, with a CEO transition underway and no major strategic shifts expected.
Qiagen Transcript: Status Update
Global leadership in sample technologies is reinforced by new automation platforms, expansion into high-growth areas like liquid biopsy and single-cell genomics, and a strong financial outlook targeting $750 million in revenue by 2028. Trusted by top researchers, the company is accelerating innovation and deepening customer relationships.